Xenon and Hypothermia Combine Additively, Offering Long-Term Functional and Histopathologic Neuroprotection After Neonatal Hypoxia/Ischemia | Zendy

Catherine Hobbs | Zendy; Marianne Thoresen | Zendy; Alexander M. Tucker | Zendy; Kristian Aquilina | Zendy; Ela Chakkarapani | Zendy; John Dingley | Zendy

Open Access

Xenon and Hypothermia Combine Additively, Offering Long-Term Functional and Histopathologic Neuroprotection After Neonatal Hypoxia/Ischemia

Author(s) -

Catherine Hobbs,

Marianne Thoresen,

Alexander M. Tucker,

Kristian Aquilina,

Ela Chakkarapani,

John Dingley

Publication year - 2008

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.107.499822

Subject(s) - medicine , hypothermia , neuroprotection , ischemia , anesthesia , hypoxia (environmental) , histopathology , oxygen , pathology , chemistry , organic chemistry

Hypoxic/ischemic (HI) brain injury affects 1 to 6 per 1000 live human births, with a mortality of 15% to 20%. A quarter of survivors have permanent disabilities. Hypothermia is the only intervention that improves outcome; however, further improvements might be obtained by combining hypothermia with additional treatments. Xenon is a noble anesthetic gas with an excellent safety profile, showing great promise in vitro and in vivo as a neuroprotectant. We investigated combinations of 50% xenon (Xe(50%)) and hypothermia of 32 degrees C (HT(32 degrees C)) as a post-HI therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research